Clinical manifestations and prognostic factors in patients with gastrointestinal stromal tumors

Table 1 Immunohistochemical staining for CD117 in tumors with a previous pathologic diagnosis of leiomyoma, leiomyo-sarcoma or GIST

Previous pathologic diagnosis	CD117-positive (n) CD117-negative (n)
Leiomyoma	6 (86%)	1 (14%)
Leiomyosarcoma	14 (78%)	4 (22%)
Benign GIST	10 (77%)	3 (23%)
Malignant GIST	51 (96%)	2 (4%)
Total	81 (89%)	10 (11%)

Table 2 Previous pathologic diagnoses, tumor site, and other immunohistochemical markers in CD117-negative patients

Previous pathologic diagnosis	n	Site	CD34	SMA	S100
Leiomyoma	1	Stomach	+	-	-
Leiomyosarcoma	1	Stomach	-	-	-
	1	Small bowel	-	-	+
	1	Colon	-	-	-
	1	Other	-	+	-
Benign GIST	2	Stomach	-	-	+
	1	Stomach	+	+	+
Malignant GIST	1	Stomach	+	-	-
	1	Small bowel	-	+	-

Table 3 Age distribution of patients with CD117-positive GIST

Age range	No. of cases (n)	Percentage (%)
< 30	1	1
30-39	2	3
40-49	7	9
50-59	15	19
60-69	19	24
70-79	26	32
80-89	10	12
> 90	1	1
Total	81	100

Table 4 Correlation between tumor size and mitotic count in CD117-positive GIST

Tumor size	Mitotic counts/50 HPFa
	< 5	5-10	> 10
≤ 2 cm	10 (100%)	0	0
2 to 5 cm	14 (56%)	8 (32%)	3 (12%)
5 to 10 cm	12 (44%)	8 (30%)	7 (26%)
> 10 cm	2 (11%)	5 (26%)	12 (63%)

Pearson correlation = 0.541, P < 0.001,

^aHPF = High power fields.

Table 5 Correlation between tumor size and resectability in CD117-positive GIST

Tumor sizes	Complete resection	Incomplete resection
≤ 2 cm	10 (100%)	0
2 to 5 cm	25 (100%)	0
5 to 10 cm	18 (69%)	8 (30.8%)
> 10 cm	9 (47%)	10 (52.6%)

Pearson correlation = 0.505, P < 0.001.